AKT1 and breast cancer: Conversely, two studies showed that ST6GALNAC2 silencing inhibits the invasive ability of MDA-MB-231 breast cancer cells and of FTC-238 follicular thyroid cancer cells in vitro through the PI3K/AKT/NF-κB signaling pathway [77,78].